Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amalian SF 24 is a monophasic, fully hydrated hyaluronic acid dermal filler designed for the correction of medium to very deep wrinkles and folds, facial volume augmentation, modeling of facial contours (including nose bridge and jawline), cheek volumization, hand rejuvenation, and scar correction (such as acne scars). It is injected into the middle to deep dermis. The product uses ultra-pure hyaluronic acid obtained via biofermentation (sodium hyaluronate) with excellent biocompatibility and flow properties. The effect typically lasts between nine to twelve months. It is fully degradable by hyaluronidase if needed. Amalian fillers are free from animal components and do not require allergy testing prior to use. Developed by S&V Technologies in Germany, all products are CE-marked medical devices meeting high safety standards[1][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amalian SF 24.